The Massey Cancer Center is a matrix center located at Virginia Commonwealth University, whose mission is to provide comprehensive, cancer-focused basic, clinical, and population research, clinical services, outreach, and education to the State of Virginia and the nation. The major goals of the Cancer Center are 1) to facilitate high-quality basic, clinical, and population-based research focused on the cancer problem and 2) to promote interdisciplinary and transdisciplinary collaborations among the scientific programs and members of the Cancer Center and translate findings into more effective interventions for cancer prevention and treatment. During the last project period, NCI annual total cost funding for Cancer Center members increased from $15,777,576 to $18,011,992, and total peer-reviewed funding from $33,125,861 to $38,016,473. During this period we expanded translational and clinical research activities, increased high impact cancer-focused research, and increased transdisciplinary research. Major goals for the next grant period are to further enhance our translational-clinical research activities, increase the depth and scope of collaborative programmatic research, and intensify our research focus on the problems of health care disparities among racial, ethnic, and other underserved populations. Research activities of the Massey Cancer Center are earned out through five research programs: Cancer Cell Signaling, Cancer Molecular Genetics, Cancer Prevention and Control, Developmental Therapeutics, and Radiation Biology and Oncology. The translational programs include both basic research and either clinical/translational or applied population research so as to facilitate transdisciplinary collaboration and rapid implementation and dissemination of research findings. In order to provide support for the predominantly peer-reviewed research base of the scientific programs, the Cancer Center supports nine shared resources: Clinical Research;Biostatistics;Flow Cytometry;Biologic Macromolecule;Behavioral Measurement;Structural Biology;Transgenic/Knockout Mouse;Cancer Research Informatics and Services;and Tissue and Data Acquisition and Analysis. This application requests continuation of CCSG funding to provide partial support for these shared resources as well as for senior leadership, program leadership, administration, staff investigators, protocol-specific research, program planning and evaluation, protocol review and monitoring, data and safety monitoring, and developmental funds, which are necessary to facilitate and stimulate transdisciplinary cancer research and translation throughout the Cancer Center.

Public Health Relevance

The mission of MCC is to serve Virginia and the nation as an internationally recognized comprehensive research and treatment center dedicated to improving the quality of human life by eliminating suffering and death through development and delivery of more effective means for the detection, treatment, prevention, control and ultimate cure of cancer. The core of this mission is to facilitate interdisciplinary and transdisciplinary cancer research so as to harness the considerable intellectual talent and scientific resources of VCU and focus them on solving the nation's cancer problem.

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
5P30CA016059-33
Application #
8662703
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Ptak, Krzysztof
Project Start
Project End
Budget Start
Budget End
Support Year
33
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Ginder, Gordon D (2015) Epigenetic regulation of fetal globin gene expression in adult erythroid cells. Transl Res 165:115-25
Chen, Shuang; Zhang, Yu; Zhou, Liang et al. (2014) A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood 124:2687-97
Youniss, Fatma M; Sundaresan, Gobalakrishnan; Graham, Laura J et al. (2014) Near-infrared imaging of adoptive immune cell therapy in breast cancer model using cell membrane labeling. PLoS One 9:e109162
Teves, Maria E; Sears, Patrick R; Li, Wei et al. (2014) Sperm-associated antigen 6 (SPAG6) deficiency and defects in ciliogenesis and cilia function: polarity, density, and beat. PLoS One 9:e107271
Bie, Jinghua; Wang, Jing; Yuan, Quan et al. (2014) Liver-specific transgenic expression of cholesteryl ester hydrolase reduces atherosclerosis in Ldlr-/- mice. J Lipid Res 55:729-38
Teramachi, Jumpei; Zhou, Hua; Subler, Mark A et al. (2014) Increased IL-6 expression in osteoclasts is necessary but not sufficient for the development of Paget's disease of bone. J Bone Miner Res 29:1456-65
Nakagawa, Akito; Lui, Francine E; Wassaf, Dina et al. (2014) Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling. ACS Chem Biol 9:2318-25
Sarkar, S; Azab, B; Quinn, B A et al. (2014) Chemoprevention gene therapy (CGT) of pancreatic cancer using perillyl alcohol and a novel chimeric serotype cancer terminator virus. Curr Mol Med 14:125-40
Dhall, Sandeep; Do, Danh; Garcia, Monika et al. (2014) A novel model of chronic wounds: importance of redox imbalance and biofilm-forming bacteria for establishment of chronicity. PLoS One 9:e109848
Rahmani, Mohamed; Aust, Mandy Mayo; Benson, Elisa C et al. (2014) PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clin Cancer Res 20:4849-60

Showing the most recent 10 out of 215 publications